Potassium-competitive acid blocker versus proton pump inhibitor with bismuth quadruple therapy for H. pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with confirmed H. pylori infection who have not had prior eradication treatment will receive bismuth-based quadruple therapy that includes either a potassium-competitive acid blocker (P-CAB) or a proton pump inhibitor (PPI) alongside bismuth, metronidazole, and tetracycline. The trial compares eradication rates using stool antigen or urea breath testing, and records safety events and patient adherence. P-CABs such as vonoprazan provide rapid and consistent acid suppression regardless of CYP2C19 genotype, which may affect treatment success. Outcomes will determine whether replacing the PPI with a P-CAB improves cure rates or tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥18 years.
* Both sexes.
* Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).
* No prior eradication therapy.

Exclusion Criteria:

* Prior Helicobacter pylori treatment.
* Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.
* Gastric surgery history.
* Major organ failure.
* Pregnancy or lactation.
* Known allergy to study drugs.

Where it's running

• Tanta University
  Tanta, El-Gharbia, Egypt Recruiting

Study contacts

• Study coordinator: Mohamed G Flefel, MD
• Email: mohamed.galal@med.tanta.edu.eg
• Phone: 00201009156988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Proactive pharmacist e-consults to optimize lung health for people with HIV

  This trial tests whether proactive pharmacist-led e-consults can help people with HIV improve lung-health medications, vaccinations, smoking cessation, and deprescribing of certain inhaled medicines or PPIs.

  Recruiting Seattle Institute for Biomedical and Clinical Research · Boise, Idaho and 2 other locations · NCT07507435

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

• P-CABs plus bismuth quadruple treatment for Helicobacter pylori infection

  This study tests whether using potassium-competitive acid blockers (P-CABs) in bismuth-containing quadruple therapy works better and is safe for adults with H. pylori infection.

  Recruiting Qilu Hospital of Shandong University · Jinan · NCT07285096

• Bismuth versus no bismuth for treating H. pylori-related stomach and duodenal ulcers in children

  This project will try adding bismuth to standard antibiotic and PPI treatment to see if it helps clear H. pylori and heal ulcers in children.

  Recruiting Can Tho University of Medicine and Pharmacy · Can Tho · NCT07260006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.